CytoSorbents Valuation Multiples

CytoSorbents is valued at $12M as of October 2026, a 1.0x revenue multiple. In the last 12 months, CytoSorbents revenue was $38M and CytoSorbents EBITDA was ($9M).

CytoSorbents Overview

About CytoSorbents

CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.


Founded

2014

HQ

United States

Employees

129

Financials (LTM)

Revenue: $38M
EBITDA: ($9M)

EV

$37M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

CytoSorbents Financials

CytoSorbents reported last 12-month revenue of $38M and negative EBITDA of ($9M).

In the same LTM period, CytoSorbents generated $28M in gross profit, ($9M) in EBITDA losses, and had net loss of ($13M).

Revenue (LTM)


CytoSorbents P&L

In the most recent fiscal year, CytoSorbents reported revenue of $37M and EBITDA of ($4M).

CytoSorbents is unprofitable as of last fiscal year, with gross margin of 71%, EBITDA margin of (12%), and net margin of (22%).

See analyst estimates for CytoSorbents
LTMLast FY202320242025202620272028
Revenue$38M$37M$31M$36M$37M
Gross Profit$28M$26M$22M$25M$26M
Gross Margin73%71%71%70%71%
EBITDA($9M)($4M)($28M)($19M)($4M)
EBITDA Margin(23%)(12%)(90%)(54%)(12%)
EBIT Margin(27%)(38%)(103%)(46%)(38%)
Net Profit($13M)($8M)($29M)($21M)($8M)
Net Margin(33%)(22%)(94%)(58%)(22%)
Net Debt-$11M---

Financial data powered by Morningstar, Inc.

CytoSorbents Stock Performance

CytoSorbents has current market cap of $12M, and enterprise value of $37M.

Market Cap Evolution


CytoSorbents' stock price is $3.79.

CytoSorbents share price decreased by 2.7% in the last 30 days, and increased by 377.6% in the last year.

CytoSorbents has an EPS (earnings per share) of $-2.60.

See more trading valuation data for CytoSorbents
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$37M$12M-1.9%-2.7%951.5%377.6%$-2.60

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

CytoSorbents Valuation Multiples

CytoSorbents trades at 1.0x EV/Revenue multiple, and (4.1x) EV/EBITDA.

See NTM and 2027E valuation multiples for CytoSorbents

EV / Revenue (LTM)


CytoSorbents Financial Valuation Multiples

As of October 9, 2026, CytoSorbents has market cap of $12M and EV of $37M.

CytoSorbents has a P/E ratio of (0.9x).

LTMLast FY202320242025202620272028
EV/Revenue1.0x1.0x1.2x1.0x1.0x
EV/EBITDA(4.1x)(8.5x)(1.3x)(1.9x)(8.5x)
EV/EBIT(3.6x)(2.6x)(1.2x)(2.2x)(2.6x)
EV/Gross Profit1.3x1.4x1.7x1.5x1.4x
P/E(0.9x)(1.5x)(0.4x)(0.6x)(1.5x)
EV/FCF-(2.9x)(1.6x)(2.4x)(2.9x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified CytoSorbents Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

CytoSorbents Margins & Growth Rates

CytoSorbents grew revenue by 5% and EBITDA by 76% in the last fiscal year.

In the most recent fiscal year, CytoSorbents reported gross margin of 71%, EBITDA margin of (12%), and net margin of (22%).

See estimated margins and future growth rates for CytoSorbents

CytoSorbents Margins

Last FY202420252026202720282029
Gross Margin71%70%71%73%
EBITDA Margin(12%)(54%)(12%)(20%)
EBIT Margin(38%)(46%)(38%)(26%)
Net Margin(22%)(58%)(22%)(36%)
FCF Margin(35%)(42%)(35%)-

CytoSorbents Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth5%15%4%5%
Gross Profit Growth7%13%6%7%
EBITDA Growth76%(31%)(77%)76%
EBIT Growth(28%)(49%)(13%)(28%)
Net Profit Growth70%(29%)(60%)70%
FCF Growth-(33%)(15%)-

Data powered by FactSet, Inc. and Morningstar, Inc.

CytoSorbents Operational KPIs

CytoSorbents' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.3M for the same period.

CytoSorbents' Rule of 40 is (15%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

CytoSorbents' Rule of X is (8%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for CytoSorbents
LTMLast FY202320242025202620272028
Rule of 40(13%)(15%)---
Bessemer Rule of X3%(8%)---
Revenue per Employee-$0.3M---
Opex per Employee-$0.3M---
G&A Expenses to Revenue--122%--
R&D Expenses to Revenue14%14%50%21%14%
Opex to Revenue-111%173%116%111%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

CytoSorbents Competitors

CytoSorbents competitors include Geratherm Medical, Observe Medical, Impedimed, CelLBxHealth, Arcoma, Pulsenmore, Genomtec, ViroGates, Iconovo and Milton Essex.

Most CytoSorbents public comparables operate across Medical Devices, DeepTech and HealthTech.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Geratherm Medical$18M$236K0.2x0.3x18.0x3.1x
Observe Medical$2M($3M)8.3x-(5.2x)-
Impedimed$10M($12M)1.3x1.2x(1.2x)(1.3x)
CelLBxHealth$2M($21M)6.0x4.2x(0.5x)(1.1x)
Arcoma$13M$1M0.6x0.5x5.8x5.0x
Pulsenmore$13M($5M)----
Genomtec$5K($2M)1850.2x-(5.2x)-
ViroGates$1M($2M)6.4x-(5.4x)-

This data is available for Pro users. Sign up to see all CytoSorbents competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About CytoSorbents

When was CytoSorbents founded?CytoSorbents was founded in 2014.
Where is CytoSorbents headquartered?CytoSorbents is headquartered in United States.
How many employees does CytoSorbents have?As of today, CytoSorbents has over 129 employees.
Who is the CEO of CytoSorbents?CytoSorbents' CEO is Phillip P. Chan.
Is CytoSorbents publicly listed?Yes, CytoSorbents is a public company listed on Nasdaq.
What is the stock symbol of CytoSorbents?CytoSorbents trades under CTSO ticker.
When did CytoSorbents go public?CytoSorbents went public in 2005.
Who are competitors of CytoSorbents?CytoSorbents main competitors include Geratherm Medical, Observe Medical, Impedimed, CelLBxHealth, Arcoma, Pulsenmore, Genomtec, ViroGates, Iconovo, Milton Essex.
What is the current market cap of CytoSorbents?CytoSorbents' current market cap is $12M.
What is the current revenue of CytoSorbents?CytoSorbents' last 12 months revenue is $38M.
What is the current revenue growth of CytoSorbents?CytoSorbents revenue growth (NTM/LTM) is 11%.
What is the current EV/Revenue multiple of CytoSorbents?Current revenue multiple of CytoSorbents is 1.0x.
Is CytoSorbents profitable?No, CytoSorbents is not profitable.
What is the current EBITDA of CytoSorbents?CytoSorbents has negative EBITDA and is not profitable.
What is CytoSorbents' EBITDA margin?CytoSorbents' last 12 months EBITDA margin is (23%).
What is the current EV/EBITDA multiple of CytoSorbents?Current EBITDA multiple of CytoSorbents is (4.1x).
How many companies CytoSorbents has acquired to date?CytoSorbents hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies CytoSorbents has invested to date?CytoSorbents hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to CytoSorbents

Lists including CytoSorbents

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial